Nanollose Ltd. AI Stock Analysis
Want to see AU:NC6 full AI Analyst Report?
Nanollose Ltd. (NC6) AI Stock Analysis
Nanollose Ltd.
(ASX:NC6)
The overall score is heavily pressured by the company's dire financial state, marked by zero revenue and accelerating cash burn that threatens its recently recapitalized balance sheet. The lack of earnings and dividends further weighs on the valuation. The primary support for the score comes from positive technical momentum, with the stock trading above key moving averages, though this is tempered by an overbought stochastic signal.
Nanollose Ltd. (NC6) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 24.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 92.04K
- Price to Earnings (P/E)
- -8.3
- Beta (1Y)
- -0.04
- Revenue Growth
- ―
- EPS Growth
- -5.88%
- Country
- Australia
- Employees
- 1
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Biotechnology
Nanollose Ltd. Business Overview & Revenue Model
Company Description
Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology. Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without re...
Nanollose Ltd. Financial Statement Overview
Summary
Financial health is critically weak. The company has zero revenue, accelerating cash burn (TTM operating cash flow of -A$1.8M), and deeply negative margins. The only positive is a recent recapitalization that restored a modest positive equity of A$1.2M with negligible debt, but the high cash consumption rate threatens this capital base quickly.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
5Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 12.50K | 412.16K | 224.61K |
| Gross Profit | -14.56K | -14.57K | -35.83K | -779.20K | 58.29K | -223.55K |
| EBITDA | -2.68M | -2.68M | -1.59M | -1.10M | -1.68M | -1.72M |
| Net Income | -2.39M | -2.39M | -1.43M | -1.16M | -1.35M | -1.57M |
Balance Sheet | ||||||
| Total Assets | 1.42M | 1.42M | 747.79K | 241.95K | 633.24K | 1.91M |
| Cash, Cash Equivalents and Short-Term Investments | 1.33M | 1.33M | 617.32K | 138.75K | 548.25K | 1.59M |
| Total Debt | 7,172 | 7,172 | 13.09K | 42.53K | 11.52K | 38.09K |
| Total Liabilities | 225.40K | 225.40K | 351.38K | 465.64K | 181.61K | 181.51K |
| Stockholders Equity | 1.20M | 1.20M | 396.41K | -223.69K | 451.63K | 1.73M |
Cash Flow | ||||||
| Free Cash Flow | -1.80M | -1.80M | -1.10M | -900.95K | -1.01M | -1.39M |
| Operating Cash Flow | -1.80M | -1.80M | -1.10M | -900.95K | -1.01M | -1.38M |
| Investing Cash Flow | 0 | 0 | 0 | 15.97K | 0 | -5,352 |
| Financing Cash Flow | 2.51M | 2.51M | 1.58M | 475.49K | -26.57K | -32.69K |
Nanollose Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NC6, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 19.29 is Positive, neither overbought nor oversold. The STOCH value of -29.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NC6.
Nanollose Ltd. Peers Comparison
Overall Rating
AU:AVE49Neutral
AU:TRP47Neutral
AU:NC646Neutral
AU:OCC44Neutral
AU:BOT38Underperform
AU:ADO31Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| 49Neutral | AUD 46.36M | -8.00 | -211.39% | ― | -46.59% | 9.09% | |
| 47Neutral | AUD 5.86M | -1.24 | -52.04% | ― | 32.22% | -26.53% | |
| 46Neutral | AUD 24.59M | -8.33 | -465.54% | ― | ― | -5.88% | |
| 44Neutral | AUD 155.26M | -10.75 | -36.83% | ― | 51.07% | -47.63% | |
| 38Underperform | AUD 22.10M | -0.25 | -118.74% | ― | 499.47% | 31.20% | |
| 31Underperform | AUD 52.28M | -11.43 | -77.75% | ― | -51.74% | 24.00% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:NC6 | Nanollose Ltd. | 0.06 | 0.01 | 20.00% | |
| AU:OCC | Orthocell Ltd | 0.56 | -0.44 | -44.50% | |
| AU:TRP | Tissue Repair Ltd | 0.11 | -0.19 | -63.33% | |
| AU:ADO | AnteoTech Ltd | 0.02 | -0.00 | -15.79% | |
| AU:AVE | Avecho Biotechnology Limited | 0.01 | 0.00 | 30.00% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.11 | -91.67% |
Nanollose Ltd. Corporate Events
Nanollose Reports Results From 2026 Annual General Meeting
Nanollose held its 2026 Annual General Meeting in Nedlands, Western Australia, on 17 November 2026, with all resolutions decided by poll. Voting recorded 89.70% in favour of adopting the remuneration report, 92.86% for Winton Willesee’s re-election a...
Nanollose fast-tracks WA pilot facility to support microbial cellulose commercialisation
Nanollose has refined its scale-up strategy to focus on a single, company-controlled pilot facility in Western Australia to produce microbial cellulose pulp, replacing plans for a larger demonstration line and reducing capital intensity on the path t...
Nanollose Secures Stage 1 Pilot Equipment as Biomaterials Scale-Up Accelerates
Nanollose has completed procurement for all equipment required for Stage 1 of its pilot facility program in Western Australia, marking a shift from planning to execution as it builds an in-house environment to scale and optimise its microbial cellulo...
Nanollose Issues New Tranche of Unlisted Options
Nanollose Ltd., listed on the ASX under ticker NC6, operates in the advanced materials and biotechnology sector, developing sustainable, plant-free cellulose-based materials for use in textiles and other industrial applications. The company targets e...
Nanollose Expands ASX-Listed Share Base With New NC6 Securities
Nanollose Ltd. has lodged an application with the ASX for the quotation of an additional 500,000 ordinary fully paid shares under its NC6 ticker. The new securities, issued on 15 September 2026, will be admitted to trading alongside the company’s exi...
Nanollose seeks ASX quotation for 300,000 new shares
Nanollose Limited has applied for quotation of 300,000 new ordinary fully paid shares on the ASX under code NC6, with an issue date of 4 September 2026. The modest increase in quoted securities signals a small capital or equity adjustment that margin...
Nanollose widens annual loss but boosts net tangible assets
Nanollose Limited reported a net loss after tax of $2.39 million for the year ended 30 June 2026, a 68% increase from the prior year’s loss of $1.43 million, while revenue from ordinary activities remained at nil.The company’s net tangible assets ros...
Nanollose Issues 3 Million Unquoted Employee Options Under Incentive Scheme
Nanollose Limited has notified the market of the issue of 3,000,000 unquoted employee options under its incentive scheme. The options, in three tranches of 1,000,000 each, were issued on August 21, 2026 and are subject to transfer restrictions, meani...
Nanollose Streamlines Scale-Up with Single Pilot Facility to Accelerate Commercial Partnerships
Nanollose Ltd. is an advanced biomaterials company focused on scaling technology that converts microbial cellulose into fibres, fabrics and other materials for industrial use. Rather than investing in full-scale manufacturing, the company aims to com...
Nanollose Adds New Shares to ASX Quotation After Option Conversions
Nanollose Ltd. has lodged an application with the ASX for quotation of 2,544 new ordinary fully paid shares under its NC6 ticker. The shares, issued on 18 August 2026 following the exercise or conversion of existing options or other convertible secur...
Nanollose Seeks ASX Quotation for Additional 70,000 Shares
Nanollose Ltd. has applied for quotation of an additional 70,000 ordinary fully paid shares on the ASX, with an issue date of 18 August 2026. The modest increase in quoted securities slightly expands the company’s free float and may improve share liq...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026
